MODIFIED FORMULATION OF FEBUXOSTAT: IMPROVED EFFICACY AND SAFETY
Keywords:
Febuxostat, Modified release, Gout, hyperuricaemia, Wagner-NelsonAbstract
Objective: Febuxostat, a xanthine oxidoreductase inhibitor, is a drug of choice for hyperuricemia and Gout. But it also suffers from drawbacks in terms of pharmacokinetic profile and toxicity. It is available as immediate release formulation in the market. The objective is to develop a modified release formulation of febuxostat that can serve the dual purpose of increasing the efficacy and decreasing the toxicity, thereby improving safety.
Methods: Pharmacokinetic and pharmacodynamic data, including drug concentration profile, efficacy data and toxicity data have been reviewed thoroughly. Based on available data, target pharmacokinetic profile has been identified as about 50 % reduction in Cmax and improvement in plasma drug concentration above required level during 6-24 hour. Desired in-vitro dissolution profile has been selected, and formulation modification has been sought to achieve the desired profile. The formulation has been prepared with a partial dose in the form of immediate release (IR) and remaining dose as an extended release (ER). IR and ER formulations have been developed separately and combined to form Inlay tablets containing ER inner tablet surrounded by IR.
Results: Based on dissolution data and Wagner-Nelson calculations, the plasma concentration profile has been predicted for the developed formulation. It reconfirms that developed formulation will achieve the desired objectives. Formulation stability has been established up to 6 months under accelerated conditions.
Conclusion: The developed formulation is a potential candidate for filing to a regulatory agency with the advantage of higher efficacy and less toxicity, which will be beneficial to the patient population and has good commercial viability.
Â
Downloads
References
Patent applications US; 2011/0311620 and EP2582812 A0; 2011.
Febuxostat for the management of hyperuricemia in people with gout, National institute for health and care excellence, NICE technology appraisal guidance 164, United Kingdom. Available from: www.guidance.nice.org.uk/ta164. [Last accessed on 10 Apr 2015].
CHMP assessment report for adenuric, Procedure no. EMEA/H/C/777. Doc Ref: EMEA/258531/2008. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR-Public_assessment_report/human/000777/ WC500021815 .pdf. [Last accessed on 10 Aug 2014].
Cristofer E, Bryan TE, Ken O, Tomoko N, Takeshi N, Emil FP. Crystal structures of bovine milk xanthine dehydrogenase A and xanthine oxidase: structure-based mechanism of conversion. Proc Natl Acad Sci USA 2000;97:10723-8.
Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricaemia. Risks and consequences in the normative aging study. Am J Med 1987;82:421–6.
Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64:2399-416.
Mazzali M, Hughes J, Kim YG, Jefferson J, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101-6.
Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol 2002;282:F991-7.
Gray CL, Walters-Smith NE. Febuxostat for the treatment of chronic gout. Am J Health Syst Pharm 2011;68:389-98.
Audit support for febuxostat for the management of hyperuricemia in people with gout, National institute for health and care excellence. NICE technology appraisal guidance 164, United Kingdom. Available from: www.guidance.nice.org.uk/ta164. [Last accessed on 10 Apr 2014].
Uloric, Takeda Pharmaceuticals America, Inc. Available from: https://www.uloric.com/. [Last accessed on 10 Apr 2014].
Drugs@fda, 021856s000_Clin Pharm R_P3. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021856s000_ClinPharmR_P3.pdf. [Last accessed on 10 Apr 2014].
Drugs@fda, 021856s000_Cross R. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021856s000_CrossR.pdf. [Last accessed on 10 Apr 2014].
Das NG, Das SK. Controlled-Release of Oral Dosage Forms. Formulation, Fill & Finish; 2003. Available from: www.pharmtech.com, http://pharmtech.findpharma.com/pharmtech/data/articlestandard/pharmtech/232003/59302/article.pdf. [Last accessed on 10 Apr 2014].
Marroum PJ. Regulatory issues relating to modified-release drug formulations (chapter 80). In: Rathbone MJ, Hadgraft J, Roberts MS. editors. Modified-release drug delivery technology. New York: Marcel Dekker; 2003. p. 943-76.
Shahi SR, Madkar VM, Kshirsagar PN, Khadbadi SS. Development and evaluation of bilayer floating tablets of Diltiazem HCl. Int J Pharm Pharm Sci 2014;6:62-5.
Brahma CK, Gali VS. Design formulation and evaluation of chrono-therapeutic drug delivery system of carbamazepine treatment for epileptic seizures. Int J Res Pharm Sci 2012;3:661-9.
Wagner JG. Application of wagner-nelson absorption method to the two-compartment open model. J Pharmacokinet Pharmacodyn 1974;2:469-86.
Gohel M, Devadia R, Parikh D, Zinzuwadia M, Soni C, Sarvaiya K, et al. Simplified mathematical approach for back calculation in Wagnor-Nelson method: application in in-vitro and in-vivo correlation (IVIVC) and formulation development work. Pharmainfo.net; 2005;3. Available from: http://www. pharmainfo.net/reviews/simplified-mathematical-approach-back-calculation-wagner-nelson-method. [Last accessed on 10 Apr 2014].
Cardot JM, Davit BM. In vitro-In vivo correlations: tricks and traps. AAPS J 2012;14:491-9.
Buskirk GAV, Asotra S, Balducci C, Basu P, DiDonato G, Dorantes A, et al. Best practices for the development, scale-up, and post-approval change control of IR and MR dosage forms in the current quality-by-design paradigm. AAPS PharmSciTech 2014;15:665-93.
Wagner JG, Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. Am J Pharmacol Sci 1964;53:1392-403.
Labeling information–Uloric. Available from: http://www. accessdata.fda.gov/drugsatfda_docs/nda/2009/021856s000_Lbl.pdf. [Last accessed on 10 Aug 2014].
Patel KN, Mehta TA. A review on oral osmotically driven system. Int J Pharm Pharm Sci 2013;5:1005-13.
Kale R, Bajaj A, Mathew D. Development of matrix diffusion controlled drug delivery system of pentoxifylline. Int J Pharm Pharm Sci 2010;2:122-30.
Goswami K, Khurana G, Marwaha RK, Gupta M. Matrix tablet of diclofenac sodium. Int J Pharm Pharm Sci 2014;6:296-301.
Patel R, Baria A. Formulation development and Process optimization of Theophylline sustained release matrix tablet. Int J Pharm Pharm Sci 2009;1:30-42.
Meka VS, Dharmalingam SR, Sheshala R, Gorajana A. Study on the effect of hydrophilic polymers and diluents in the development of oral sustained drug delivery system of febuxostat. Eur J Sci Res 2014;118:326-35.
Kulkarni A, Bhatia M. Development and evaluation of regioselective bilayer floating tablets of atenolol and Lovastatin for biphasic release profile. Iran J Pharm Res 2009;8:15-25.
Prasad MSC, Babu BN, Ajay M, Raj SB, Audinarayana N, Reddy KB. Design and characterization of modified release isoniazid and salbutamol sulphate inlay tablet. Int J Pharm Pharm Sci 2011;3:153-9.
Manoranjan S. Formulation of dual component drug delivery of glimepiride and metformin hydrochloride for immidiate and sustain release. Int J Res Ayurveda Pharm 2010;1:624-33.
Patent applications CN101773498B and CN102641255A.